成人急性白血病自体造血干细胞移植中国专家共识(2024年版)  

Chinese consensus on autologous stem cell transplantation for adult acute leukemia(2024)

作　　者：中华医学会血液学分会造血干细胞应用学组 黄晓军[2] 吴德沛[3] 张晓辉[2] 姜尔烈 Stem Cell Application Group,Chinese Society of Hematology,Chinese Medical Association;Huang Xiaojun;Wu Depei;Zhang Xiaohui;Jiang Erlie(不详;Peking University People's Hospital,Peking University Institute of Hematology,Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation,National Clinical Research Center for Hematologic Disease,Beijing 100044,China;Department of Hematology,the First Affiliated Hospital of Soochow University,Jiangsu Institute of Hematology,National Clinical Research Center for Hematologic Disease,Suzhou 215006,China;Peking University People's Hospital,Peking University Institute of Hematology,Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation,National Clinical Research Center for Hematologic Disease,Bejing 100044,China;Institute of Hematology&Blood Diseases Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,National Key Laboratory of Blood and Health,Haihe Laboratory of Cell Ecosystem,Tianjin Medical and Health Research Institute,National Clinical Research Center for Hematologic Disease,Tianjin 300020,China)

机构地区：[1]不详 [2]北京大学人民医院血液科,北京大学血液病研究所,北京市造血干细胞移植重点实验室,国家血液系统疾病临床医学研究中心,北京100044 [3]苏州大学附属第一医院血液科,江苏省血液研究所,国家血液系统疾病临床医学研究中心,苏州215006 [4]中国医学科学院血液病医院(中国医学科学院血液学研究所),血液与健康全国重点实验室,细胞生态海河实验室,天津医学健康研究院,国家血液系统疾病临床医学研究中心,天津300020

出　　处：《中华血液学杂志》2024年第7期637-644,共8页Chinese Journal of Hematology

摘　　要：自体造血干细胞移植(autologous stem cell transplantation,ASCT)是成人急性白血病(AL)缓解后治疗的方法之一。与异基因造血干细胞移植(allo-HSCT)相比,ASCT具有不受供者限制、不发生移植物抗宿主病(GVHD)、移植相关死亡率低等优点;与多疗程的巩固化疗相比,ASCT能显著缩短治疗时间、减轻患者经济负担,提升患者生活质量。但目前,我国成人AL患者接受ASCT数量较少。为提高临床医师对ASCT在成人AL治疗中作用和地位的认识,提高ASCT临床疗效,亟待制定我国成人急性白血病自体造血干细胞移植专家共识。Autologous stem cell transplantation(ASCT)emerges as a therapeutic strategy following remission in adult acute leukemia(AL).It offers advantages over allogeneic hematopoietic stem cell transplantation(allo-HSCT),including independence from donor availability,absence of graft-versus-host disease(GVHD),and a reduced risk of transplant-related mortality.Furthermore,when juxtaposed with the extended regimens of consolidation chemotherapy,ASCT stands out by markedly abbreviating treatment duration,alleviating the economic strain on patients,and enhancing their overall quality of life.Despite these benefits,the adoption of ASCT among adult AL patients in China remains disproportionately low.To enhance clinical physicians'understanding of the role and position of ASCT in AL management and to improve the clinical efficacy of ASCT,it is urgent to establish a consensus among experts on ASCT for adult acute leukemia in our nation.

关 键 词：自体造血干细胞移植 成人急性白血病 巩固化疗 临床医师 异基因造血干细胞移植 中国专家共识 患者生活质量 临床疗效 

分 类 号：R733.71[医药卫生—肿瘤] R457.7[医药卫生—临床医学]